Press releases

16
Mar 2016
20:30 E.S.T.

Cellectis and MabQuest Announce Immunotherapy Partnership on New Class of PD-1 Antagonist Monoclonal Antibodies

Read more
14
Mar 2016
20:30 E.S.T.

Cellectis Reports Fourth Quarter and Full Year 2015 Financial Results

Read more
8
Mar 2016
21:30 E.S.T.

Cellectis Announces Presentation at the Cowen and Company 36th Annual Health Care Conference in Boston, March 7-9, 2016

Read more
2
Mar 2016
21:30 E.S.T.

Cellectis Subsidiary Calyxt, Acquires Land for New Headquarters Facility

Read more
19
Jan 2016
21:30 E.S.T.

Cellectis Enters into New Agreement with CELLforCURE for the cGMP Manufacturing of UCART123 for Hematological Malignancies

Read more
11
Jan 2016
21:30 E.S.T.

Cellectis Announces a New CAR Architecture Controlling CAR T-Cell Functions

Read more
7
Jan 2016
21:30 E.S.T.

Cellectis Announces Chief Medical Officer Appointment to Senior Leadership Team

Read more
23
Dec 2015
21:30 E.S.T.

Cellectis Files First Clinical Trial Application for UCART19, an Allogeneic Gene Edited CAR T-Cell Product for Hematological Malignancies

Read more
21
Dec 2015
21:30 E.S.T.

Cellectis Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, January 11 – 14, 2016

Read more
19
Nov 2015
21:30 E.S.T.

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US